Introduction {#S0001}
============

Asthma is a heterogeneous disease for which recognizable clusters of demographic, clinical and/or pathophysiological characteristics -- often called "phenotypes" or "endotypes"- have been defined.[@CIT0001],[@CIT0002] The treatment goal is achieving asthma control (i.e. good control of symptoms and minimization of the risk of exacerbations).[@CIT0001],[@CIT0003] However, despite treatment guidelines, asthma remains uncontrolled in many patients.[@CIT0004] Asthma severity is assessed according to the level of treatment required to achieve and maintain asthma control. However, the definition of severe or therapy-refractory asthma is not straightforward and has not been consistent across studies.[@CIT0005] Nowadays, the most accepted definition of severe asthma is that requiring high-dose inhaled corticosteroids (ICS) plus a second controller and/or systemic corticosteroids to prevent it from becoming "uncontrolled" or which remains "uncontrolled" despite this therapy (refractory).[@CIT0001],[@CIT0003] Patients with severe asthma are at risk of severe exacerbations and even death.[@CIT0001] Severe asthma has a profound personal, clinical and economic impact.[@CIT0001],[@CIT0003],[@CIT0006]

Allergic asthma accounts for most cases of asthma, with immunoglobulin E (IgE) being integral to its physiopathology.[@CIT0007],[@CIT0008] Allergic asthma is associated with increased levels of circulating total and specific IgE, with a clear involvement both at the onset of the disease and during its chronic phase.[@CIT0007] Omalizumab, the first treatment addressing the allergic component of moderate-to-severe allergic asthma,[@CIT0009] is an anti-IgE monoclonal antibody that selectively binds to human IgE and prevents its binding to high-affinity IgE receptors.[@CIT0010] In the randomized, Phase III trial INNOVATE,[@CIT0011] omalizumab significantly reduced the rate of clinically significant and severe asthma exacerbations and emergency visits and significantly improved asthma-related quality of life, morning peak expiratory flow and asthma symptom scores vs. placebo in patients with severe persistent asthma, with a good safety profile.[@CIT0011] Omalizumab is indicated in Europe as an add-on therapy to improve asthma control only in patients with severe persistent allergic asthma.[@CIT0010] A meta-analysis of 25 non-controlled studies published up to 2015 and a recent systematic review (2018) that updates and extends this review up 42 of such studies confirm the effectiveness of omalizumab in the real-life setting.[@CIT0012],[@CIT0013]

An observational, multicentre, retrospective study was conducted between 2015 and 2016 in Spain in 345 adult patients with severe persistent asthma who had achieved total disease control as soon as after one-year treatment with omalizumab (FENOMA study). This study underlined the heterogeneity of patients achieving this treatment goal with omalizumab in the real-life clinical setting.[@CIT0014] In the current study, we describe the clinical improvement of patients with allergic asthma (Immunoglobulin \[Ig\] E-mediated asthma) --i.e. in whom omalizumab was strictly administered following therapeutic indication[@CIT0010]- who participated in the FENOMA study. Treatment-response biomarkers such as total IgE, peripheral blood eosinophil count and exhaled nitric oxide fraction (FeNO)[@CIT0008],[@CIT0015] were also assessed.

Methods {#S0002}
=======

Study Design and Subjects {#S0002-S2001}
-------------------------

FENOMA (\[FENOtipos de asMA\], Asthma Phenotypes) was an observational, retrospective, real-life study, carried out in 69 Spanish centres. Design of this study has been previously published.[@CIT0014] Briefly, patients included where those ≥18 years, with severe persistent asthma (steps 5 or 6 according to the Spanish Guidelines on the Management of Asthma 2009),[@CIT0016] having started treatment with omalizumab (as per usual practice) between 1st January 2010 and 31st December 2013, and who had achieved control of the disease after finishing the first year of treatment with omalizumab. Asthma control was defined according to Spanish reference guidelines,[@CIT0016] which include fulfilling all of the following criteria: no daytime asthma symptoms or asthma symptoms ≤ twice a week, no limitation in activities of daily living, no night-time asthma symptoms/awakenings, no need for rescue medication or ≤ twice a week, normal pulmonary function (forced expiratory volume in 1 s \[FEV~1~\] ≥80% of the predicted value/peak expiratory flow \[PEF\] \>80% of their personal best) and no severe or clinically significant exacerbations. The only exclusion criterion was having participated in a clinical trial during the period of analysis. Of the 345 patients included in the FENOMA study, 240 (69.6%) had allergic asthma (i.e. positive skin prick test or specific IgE and symptomatology associated with exposure), and should have serum IgE level between 30 and 1500 IU/mL. This population was included in the present study. A positive skin prick test was defined as an immediate hypersensitivity to commonly tested environmental aeroallergens. These are likely to have slightly varied among centers.

The study was conducted according to Good Clinical Practice (International Conference of Harmonization) guidelines and local regulation and was approved by the Independent Ethic Committee of the Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. All participants provided written informed consent.

Information Collected {#S0002-S2002}
---------------------

Medical records were reviewed between February 2015 and June 2016. Data collected before treatment (baseline) included: demographics and anthropometrics, smoking habit (never, former (≥1 year), current), clinical history including asthma-related co-morbidities (allergic rhinitis, sinus polyposis, atopic dermatitis), family history (atopy and mental/psychosocial disorders), total serum IgE level. Data collected before and after one-year treatment with omalizumab included: anthropometrics, severity and control of the disease (including data from the Spanish validated version of the Asthma Control Test \[ACT\][@CIT0017],[@CIT0018] when available), pulmonary function (FEV~1~), the percentage of blood eosinophil count, FeNO, the number of non-severe exacerbations and the use of healthcare resources due to these episodes. The need for rescue medication and the treatment with ICS and oral corticosteroids (OCS) were also captured. OCS intake before receiving treatment with omalizumab was defined either as having a daily maintenance dose or a short course of treatment.

Study Outcomes {#S0002-S2003}
--------------

Primary outcome of this analysis was to describe the clinical and pulmonary improvement of patients that had achieved control disease after one-year treatment with omalizumab by means of i) incidence of daytime symptoms, ii) changes in the use of ICS or OCS, iii) need of rescue therapy, iv) pulmonary function (FEV~1~), iv) number of non-severe exacerbations and vi) use of healthcare resources: non-planed visits to primary care or specialists and the number of days of school or workplace absenteeism due to asthma worsening. Non-severe asthma exacerbations were defined as those that did not require OCS, emergency assistance or hospitalization. Secondary outcomes include the assessment of the level of asthma control by means of the ACT questionnaire and the percentage of blood eosinophil blood count before and after treatment and FeNO.

Statistical Analysis {#S0002-S2004}
--------------------

Continuous variables are presented as mean, standard deviation (SD) and 95% confidence interval (CI), or median and quartile 1 (Q1) and 3 (Q3), as applicable. Categorical variables are reported as frequencies and percentages. Descriptive statistics were calculated for demographic and clinical characteristics. For statistical comparisons, the Wilcoxon signed-rank was used as applicable. All tests were 2-sided. A P value of \<0.05 was considered to be statistically significant. All analyses were performed with the SAS statistical package (version 9.4; SAS Institute, Cary, NC).

Results {#S0003}
=======

Patients Included and Baseline Characteristics {#S0003-S2001}
----------------------------------------------

Demographic, anthropometric and clinical characteristics of patients who had achieved total control after one-year treatment with omalizumab are shown in [Table 1](#T0001){ref-type="table"}. Mean (SD) age of patients was 45.4 (15.0) years. Sixty-seven percent (n=161) were female. Most patients (81.7%) had never smoked. Median time (Q1;Q3) between asthma and severe persistent asthma diagnoses was 9.8 (3.3;19.1) years. Median (Q1;Q3) time since diagnosis of severe persistent asthma was 5.6 (4.2;7.4) years. Forty percent of patients had a familial history of atopy. The most frequent comorbidity was allergic rhinitis (77.1%). Nearly half of patients (48.5%) showed hyper-reactivity to mites and 26.7% to pollens.Table 1Demographic, Anthropometric and Clinical Characteristics at BaselineVariableN=240Age, years, mean (SD)45.4 (15.0)Sex, female, n (%)161 (67.1)Smoking Status^a^, n (%) Never smoked196 (81.7) Former (≥ 1 year)36 (15.0) Time since have quitted, years, mean (SD)11.7 (5.9) Current smoker8 (3.3) Packages/year, mean (SD) smoking, years, mean (SD)7.1 (12.8)BMI (kg/m^2^)^b^, mean (SD)27.1 (5.6)Time Since Diagnosis of\*: Asthma, years, median (Q1, Q3)16.3 (9.8; 26.3) Severe persistent asthma, years, median (Q1, Q3)5.6 (4.2; 7.4)Family history of atopy^c^, n (%)96 (40.0)Family history of mental/psychosocial disorders5 (2.1)Comorbidities, n (%) Allergic rhinitis185 (77.1) Sinonasal polyposis45 (18.7) Chronic sinusitis27 (11.2) Atopic dermatitis27 (11.2) Gastroesophageal reflux^d^21 (8.7) Sleep apnea syndrome9 (3.7) Depression16 (6.7)IgE levels, IU/mL, median (Q1;Q3)302.5 (154.0; 553.5)[^1]

Asthma characteristics in the year before starting treatment with omalizumab are shown in [Table 2](#T0002){ref-type="table"}. Almost all patients (98%; n=235) had daytime symptoms, with nearly half (48.7%; n=117) having daily symptoms and 17.1% (n=41) continuous symptoms. Also, almost all patients (92.3%; n=220) had night-time symptoms, with 35.8% (n=86) being more than once a week and 25.4% (n=61) frequents.Table 2Asthma History in the Year Before Starting Treatment with OmalizumabVariablesN=240Daytime Symptoms, n (%) No symptoms or symptoms ≤ twice a week5 (2.1) \> Twice a week77 (32.1) Daily symptoms117 (48.7) Continuous symptoms (several times a day)41 (17.1)Limitation in Activities of Daily Living^a^, n (%) Quite142 (59.2) No2 (0.8) Some60 (25.0) Much31 (12.9)Night-Time Symptoms^b^, n (%) No symptoms18 (7.6) ≤ twice a month26 (10.9) \> twice a month47 (19.7) \> once a week86 (36.1) Frequents61 (25.6)Need for Rescue Medication, n (%) No or ≤ 2 days a week7 (2.9) \> 2 days a week (but not everyday)89 (37.1) Everyday110 (45.8) Several times a day34 (14.2)Pulmonary Function, Median (Q1; Q3) FEV~1~, %71.5 (61.0; 84.0) Non-severe asthma episodes, median (Q1; Q3)5.0 (3.0; 8.5) Severe or clinically significant exacerbations in the previous year, median (Q1; Q3)^c^3.0 (2.0; 4.0)Use of Healthcare Resources Due to Severe or Clinically Significant Exacerbations, Mean (SD) Visits to emergency units^d^2.6 (3.9) Hospital admissions^e^0.4 (0.9) No. days of admission^f^7.4 (3.7) Intensive care units admissions^g^0.0 (0.2) No. days of admission^h^5.7 (3.8)Background Treatments for Asthma, n (%) ICS239 (99.6)  Dose, µg, median (Q1; Q3)960 (640.0; 1200.0) OCS^e^139 (58.1)  Dose, mg, median (Q1; Q3)7.7 (0.0; 30.0) Leukotriene receptor antagonist209 (87.1) LABA235 (97.9) On demand SABA229 (95.4) Theophylline20 (8.3) Immunotherapy61 (25.4) Chromones2 (0.8) Other53 (22.1)[^2]

Nearly 60% of patients (n=142) and 12.9% (n=31) had quite and much limitations in the activity of daily living, respectively. Ninety-seven percent (n=233) needed rescue medication, with 60.0% (n=144) needing medication everyday/several times a day. Median FEV~1~ was 71.5%. Median (Q1; Q3) number of non-severe asthma episodes and of severe or clinically significant exacerbations in the previous year was 5.0 (3.0; 8.5) and 3.0 (2.0; 4.0), respectively. The number of visits to emergency rooms, admission days to hospital or intensive care units due to these exacerbations is shown in [Table 2](#T0002){ref-type="table"}. Median (Q1; Q3) total serum IgE levels were 302.5 (154.0; 553.5) IU/mL. Background treatments for asthma during the previous year are shown in [Table 2](#T0002){ref-type="table"}. Mean (SD) initial dose of omalizumab was 325.9 (119.8) mg.

Outcomes After One-Year Treatment {#S0003-S2002}
---------------------------------

More than half (56.7%, n=136) of patients had no daytime symptoms, while 35.0% (n=84) and 8.3% (n=20) had symptoms 1 and 2 days per week, respectively. Up to 49.6% (n=119) of the total population evaluated stopped taking OCS, only 8.3% (n = 20) of the patients continued to receive them after one year of treatment with omalizumab (P \<0.0001). Of the patients with available information about dose modification, the reduction was not significant (P=0.3077). The proportion of patients taking ICS decreased significantly (from 99.6% to 90.2%; P \<0.0001). The dose of ICS was reduced in 58.7% (n=141) patients (P=0.9062) and maintained in 37.5% (n=90) patients. More than half (55.4%, n=133) of patients needed no rescue medication, while 35.0% (n=84) and 9.6% (n=23) needed medication 1 and 2 days per week, respectively. FEV~1~ increased a median (Q1; Q3) of 12.0% (4.0; 23.0) (P \<0.0001) ([Table 3](#T0003){ref-type="table"}).Table 3Non-Severe Exacerbations, Pulmonary Function and Use of Healthcare Resources/Absenteeism Before and After One-Year Treatment with Omalizumab (n=240)VariablesBefore TreatmentAfter TreatmentP-value\*Non-severe exacerbations, median (Q1; Q3)5.0 (3.0; 8.5)^a^0.0 (0.0; 2.0)^b^ Change-4.0 (−7.0; −2.0)\<0.0001Pulmonary function (FEV~1~%), median (Q1; Q3)71.5 (61.0; 84.0)84.0 (78.0; 94.0)^c^ Change12.0 (4.0; 23.0)\<0.0001Use of Healthcare Resources/Absenteeism Due to Non-Severe Exacerbations, Median (Q1; Q3)Unplanned visits to Primary care4.0 (2.0; 6.0)^d^0.0 (0.0; 1.0)^e^ Change−3.0 (−5.0; −1.0)\<0.0001Unplanned visits to specialists1.0 (0.0; 3.0)^e^0.0 (0.0; 0.0)^f^ Change−1.0 (−2.0; 0.0)\<0.0001School or workplace absenteeism, days0.0 (0.0; 14.0)^g^0.0 (0.0; 0.0)^h^ Change0.0 (−11.0; 0.0)\<0.0001[^3]

The number of non-severe asthma exacerbations decreased a median (Q1; Q3) of −4.0 (−7.0; −2.0); P \<0.0001. The number of unplanned visits to primary care or specialists, or days of school or workplace absenteeism before treatment is shown in [Table 3](#T0003){ref-type="table"}. After one-year treatment with omalizumab, none of these took place (P \<0.0001 vs. before treatment for school or workplace absenteeism).

Data regarding the ACT questionnaires were available in 101 (42.1%) and 117 (48.8%) patients before and after one-year treatment with omalizumab, respectively. Median score (Q1; Q3) was 14.0 (11.0; 16.0) before treatment and 22.0 (20.0; 24.0) after one-year treatment (change: 7.0 \[5.0;10.0\]).

The percentage of blood eosinophil count was available in 205 (85.4%) patients before treatment and in 132 (55.0%) after one-year treatment. Median (Q1; Q3) was 5.0% (3:0; 8.0) and 3.0 (2.0; 5.5)%, respectively (change: −1.0 \[−3.0;0.0\]). FeNO values were available in 98 (40.8%) patients before treatment and in 109 (45.4%) after one-year treatment. Median (Q1; Q3) was 36.0 (23.0; 53.0) ppb and 20.0 (13.0; 34.0) ppb, respectively (change: −14.5 \[−26.0; 0.0\]).

Discussion {#S0004}
==========

The results of our study illustrate the clinical improvement of patients with severe persistent allergic asthma who achieved full asthma control as soon as after one-year treatment with omalizumab in a real-life setting. This achievement is relevant given the difficulty in optimally controlling asthma, especially severe asthma.[@CIT0019],[@CIT0020] It also adds evidence to the benefits of omalizumab as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma under conditions of heterogeneity in patients, clinicians, sites, and treatment patterns, with results being consistent with those of other studies in the real-life setting.[@CIT0012],[@CIT0013]

Several clinical indicators related to disease control according to reference guidelines -- both objective and subjective -- improved after one-year treatment with omalizumab. The incidence of daytime symptoms was greatly reduced, with nearly 57% of patients having no daytime symptoms compared to 2% having no symptoms or ≤ twice a week before starting treatment. Nearly 50% of patients needed no OCS, which is in agreement with other studies analyzing the effectiveness of omalizumab in patients with severe persistent allergic asthma in the real-life setting.[@CIT0012] The meta-analysis gathering 25 of these studies commented above estimated a relative risk (RR) reduction of 0.46 in the requirement of OCS after 12 months of omalizumab therapy, and reported significant and small-to-moderate reductions in ICS intake.[@CIT0012] Changes in the intake of OCS or ICS were not analyzed in the INNOVATE study.[@CIT0011] The use of rescue medication was also greatly reduced, with 55% of patients needing no rescue medication compared to 3% of patients needing no rescue medication or ≤ twice a week before starting treatment. The reduction in the proportion of patients needing rescue medication was not analyzed in the INNOVATE study nor in the meta-analysis of real-life evidence. However, a reduction of 0.5 puffs/day compared to placebo was reported in the INNOVATE study, although this was not statistically significant.[@CIT0011] FEV~1~ significantly improved in a magnitude similar to that reported in 11 of the 42 real-life studies (n=1814) that analyzed this clinical parameter after 1-year treatment (average of 12.4%).[@CIT0013]

After one-year treatment with omalizumab, the number of non-severe exacerbations significantly decreased by five-fold (from a median \[Q1; Q3\] of 5.0 \[3.0; 8.5\] to 0.0 \[0.0; 2.0\]). Accordingly, the number of unplanned visits to primary or specialized care and of school or workplace absenteeism also decreased. Our results are in agreement with the reductions in healthcare resource and asthma-related absences from work/school reported in a long-term (up to 10-year) follow-up study in the real-life setting.[@CIT0021] This latter study also corroborated the overall safety profile of omalizumab,[@CIT0021] which was not analyzed in our study.

The ACT questionnaire revealed good asthma control, as assessed by both the physician and patient, with a change from 14 to 22 points in a scale from 5 to 25. This is in agreement with the favorable evaluation of treatment effectiveness by both, patients and investigators, in the INNOVATE study.[@CIT0011] Similarly, on average 73% of patients achieved a good or excellent rating in the "Global evaluation of treatment effectiveness" at 12 months treatment with omalizumab in the meta-analysis of studies in the real-life setting.[@CIT0012]

It is worth noting that patients having achieved full asthma control after one-year treatment with omalizumab presented increased peripheral blood eosinophil percentage (5%) before starting treatment, which is quite frequent in patients with asthma.[@CIT0022] This observation is in agreement with the hypothesis that IgE would be the cause of allergic asthma, as it is involved early in the inflammatory cascade activating mast cells, basophils, eosinophils and dendritic cells, while eosinophilia would be the consequence of the whole process.[@CIT0022] A post hoc analysis of the INNOVATE study showed that omalizumab produced a greater reduction in exacerbation rate (primary outcome) in patients with higher (≥300 cells/µL) vs. lower baseline eosinophil count, and even more when IgE levels were also high (\>75 IU/mL).[@CIT0023] In a pooled analysis of seven randomized controlled omalizumab trials, patients with pre-treatment total IgE ≥76 IU/mL were also more likely to experience clinically meaningful benefit to omalizumab and more patients had clinically meaningful responses.[@CIT0024] However, large studies in the real-life setting have shown that omalizumab response in patients with severe allergic asthma do not vary in patients with high or low (≤300 cells/µL) blood eosinophil count, with this finding being independent of the eosinophil cut-offs and of response definitions used.[@CIT0025],[@CIT0026] It should be noted that in our study eosinophil blood count was recorded as percentage, which limits its interpretation. A cut-off point of 2% has recently shown to be a strong predictor of eosinophilia (sensitivity of 87%; a specificity of 86%, P \< 0.001), in smokers with asthma having well-controlled disease.[@CIT0027] Median IgE was 302.5 IU/mL in our series of well-controlled patients compared to 150 IU/mL in the INNOVATE study.[@CIT0011]

The effect of omalizumab on inflammatory cells mediated by the reduction of the allergen-specific proliferative response of T-helper 2 cells (including the production of IL)[@CIT0022] may explain the reduction from 5% to 3% in eosinophil count observed after one-year treatment with omalizumab in our series. A similar reduction was also reported in the long-term follow-up study in the real-life setting commented above.[@CIT0021] These observations support the adequacy of targeting the cause of allergic asthma (IgE) instead of the consequence (eosinophilia) when treating severe allergic asthma.[@CIT0022] Novel therapies targeting IL-5 or its receptor are emerging for the treatment of severe eosinophilic asthma. However, their use is limited to patients with high blood eosinophil count (≥300 cells/µL) over 12 months.[@CIT0028] There is no blood eosinophil count threshold for the use of omalizumab.[@CIT0010]

Similar to sputum and blood eosinophils, elevated FeNO is predictive of asthma exacerbations and asthma severity.[@CIT0008] In fact, FeNO levels before treatment were above the threshold of 25 ppb (FeNO levels \<25 ppb are considered normal in adults)[@CIT0015] (median of 36.0 \[23.0; 53.0\] ppb). This observation is in agreement with the findings of a prospective, randomized, placebo-controlled study showing that patients with severe asthma and higher baseline FeNO had a greater reduction in exacerbation rate with omalizumab vs. patients with low baseline FeNO.[@CIT0021] After one-year treatment with omalizumab, FeNO levels decreased to levels below 25 ppb (20.0 \[13.0; 34.0\]) ppm. A similar reduction was also reported in the above-mentioned long-term study in the real-life setting.[@CIT0026] Nevertheless, the effectiveness of omalizumab has shown to be independent of baseline FeNO levels. It should be also considered that the reduction in exacerbation rate is not the only variable defining asthma control. Summing up, this study represents a unique real-life experience of omalizumab in patients who achieved total asthma control as soon as within 1 year, which provides information on the effectiveness of this drug in severe allergic persistent asthma. However, some limitations should be acknowledged. These include its single-arm retrospective nature, which implies relying on the accuracy and completeness of information included in the clinical records. This has especially affected biomarkers such as FeNO, which was not routinely assessed in the clinical practice at the time of the study, and the ACT questionnaire. The lack of a control group prevents corroborating findings about predictors of response.

The results of our study in patients with severe persistent allergic asthma who achieved disease control after one-year treatment with omalizumab highlight the clinical benefits achieved by these patients after this period, including the decrease of the use of medications with damaging side effects. They also support the effect of omalizumab on the reduction of the burden on healthcare systems.
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[^1]: **Notes:** ^a^n=233; ^b^n=235; ^c^n=236; ^d^n=239 Percentages are given for valid population. \*Before starting treatment with omalizumab.

    **Abbreviation:** BMI, body mass index.

[^2]: **Notes:** ^a^n=235; ^b^n=238; ^c^n=236; ^d^n=231; ^e^n=239; ^f^n=53; ^g^n=238; ^h^n=3. Percentages are given for valid population.

    **Abbreviations:** FEV~1~, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LABA, long-acting inhaled ß2-agonists; OCS, oral corticosteroids; SABA, short-acting inhaled ß2-agonists.

[^3]: **Notes:** ^a^n=224; ^b^n=234; ^c^n=238; ^d^n=209; ^e^n=226; ^f^n=233; ^g^n=180; ^h^n=217. \*Wilcoxon signed-rank test.
